Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study
Journal of the American Heart Association · 06.08.2024 · 13 (15)
DOI: 10.1161/jaha.123.034080 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 06.08.2024. Verfasst von Xudong Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital, School of Medicine Zhejiang University Zhejiang China. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Heart Septum. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported to be safe and effective at midterm follow‐up to treat drug‐refractory hypertrophic obstructive cardiomyopathy in a single center. However, data from other centers are lacking. This retrospective cohort study aimed to investigate the efficacy and safety of PIMSRA from another independent center. Methods and Results PIMSRA was performed in 76 patients with hypertrophic obstructive cardiomyopathy in our center from April 2020 to June 2023. The primary outcome was the reduction of left ventricular outflow tract gradient after 6 months or more post‐PIMSRA. Secondary outcomes were periprocedural major adverse clinical events. Sixty‐one patients returned to the hospital for follow‐up 6 to 30 (median, 14) months after the procedure. At the last follow‐up of the 61 patients, the maximum septal thickness decreased from a median of 23.6 (interquartile range, 20.5–26.4) to 19.1 (interquartile range, 16.0–22.1) mm ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital, School of Medicine Zhejiang University Zhejiang China.
- Graduate School Zhejiang University School of Medicine Hangzhou China.
ORCID-Profile: Siyuan Chen, Zhi Du, Yijiang Zhou, Xiaogang Guo
Zitieren
APA
Xie, X., Chen, S., Cui, Y., Zhou, Z., Lu, J., Du, Z., Ding, J., Xing, K., Zhang, Y., Zhou, Y., Li, J., & Guo, X. (2024). Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study. Journal of the American Heart Association, 13(15). https://doi.org/10.1161/jaha.123.034080
Vancouver
Xie X, Chen S, Cui Y, Zhou Z, Lu J, Du Z, et al. Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study. Journal of the American Heart Association. 2024;13(15). doi:10.1161/jaha.123.034080
BibTeX
@article{Xie2024,
author = {Xie, Xudong and Chen, Siyuan and Cui, Yawei and Zhou, Zhenzhen and Lu, Jianhua and Du, Zhi and Ding, Jie and Xing, Kaidi and Zhang, Yuesheng and Zhou, Yijiang and Li, Jun and Guo, Xiaogang},
title = {Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {15},
doi = {10.1161/jaha.123.034080}
}
EUVIMED